-
公开(公告)号：US20220363648A1
公开(公告)日：2022-11-17
申请号：US16973941
申请日：2019-06-25
发明人： Kevin G. Liu , Kellen L. Olszewski , Ji-in Kim , Masha V. Poyurovsky , Koi Morris , Xuemei Yu , Christopher Lamarque
IPC分类号： C07D239/42 , C07D495/04 , C07D519/00 , C07D491/048 , C07D403/12 , C07D239/94 , C07D401/12 , C07D491/052 , C07D471/04 , C07D405/12 , C07D417/12 , C07D405/14 , C07D413/12 , C07D401/14 , C07D403/04 , C07D409/12 , C07D413/14 , C07D473/34
摘要： This invention provides compounds that modulate glucose uptake activity and cellular transport/uptake of glucose, and particularly GLUTS3, but also including but not limited to GLUT1-14 (SLC2A1-SLC2A14). Compounds of the invention are useful for treating diseases, including cancer, autoimmune diseases and inflammation, infectious diseases, and metabolic diseases.
-
公开(公告)号：US20180298029A1
公开(公告)日：2018-10-18
申请号：US15737911
申请日：2016-06-24
发明人： Kellen Olszewski , Ji-Ln Kim , Masha Poyurovsky , Kevin G. Liu , Anthony Barsotti , Koi Morris
IPC分类号： C07D513/04 , C07D495/04 , C07D491/048 , C07D487/04 , C07D473/34 , C07D471/04 , A61P35/04
CPC分类号： C07D513/04 , A61K31/519 , A61K31/52 , A61K31/5377 , A61K45/06 , A61P35/04 , C07D471/04 , C07D473/34 , C07D487/04 , C07D491/048 , C07D495/04 , A61K2300/00
摘要： Provided herein are compounds that modulate glucose uptake activity and are useful for treating cancer, autoimmune diseases, inflammation, infectious diseases, and metabolic diseases. In certain embodiments, the compounds modulate glucose uptake activity by modulating cellular components, including, but not limited to those related to glycolysis and known transporters/co-transporters of glucose such as GLUT1 and other GLUT family members/alternative hexose transporters. In certain embodiments, the compounds have the structure of formula I: Formula (I) wherein the variables have the values disclosed herein.
-
公开(公告)号：US20240360085A1
公开(公告)日：2024-10-31
申请号：US18672406
申请日：2024-05-23
发明人： Kevin G. Liu , Kellen Olszewski , Ji-In Kim , Masha V. Poyurovsky , Koi Morris , Xuemei Yu , Christophe Lamarque
IPC分类号： C07D239/42 , C07D239/94 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D473/34 , C07D491/048 , C07D491/052 , C07D495/04 , C07D519/00
CPC分类号： C07D239/42 , C07D239/94 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D473/34 , C07D491/048 , C07D491/052 , C07D495/04 , C07D519/00
摘要： This invention provides compounds that modulate glucose uptake activity and cellular transport/uptake of glucose, and particularly GLUT3, but also including but not limited to GLUT1-14 (SLC2A1-SLC2A14). Compounds of the invention are useful for treating diseases, including cancer, autoimmune diseases and inflammation, infectious diseases, and metabolic diseases.
-
公开(公告)号：US20190315772A1
公开(公告)日：2019-10-17
申请号：US16397043
申请日：2019-04-29
发明人： Kellen L. Olszewski , Ji-In Kim , Masha V. Poyurovsky , Kevin G. Liu , Anthony Barsotti , Koi Morris
IPC分类号： C07D513/04 , A61P35/04 , C07D495/04 , C07D491/048 , C07D487/04 , A61K45/06 , C07D471/04 , A61K31/5377 , A61K31/52 , A61K31/519 , C07D473/34
摘要： Provided hererin are compounds that modulate glucose uptake activityand are useful for treating cancer, autoimmune diseases, inflammation, infectious diseases, and metabolic diseases. In certain embodiments, the compounds modulate glucose uptake activity by modulating cellular components, including, but not limited to those related to glycolysis and the known transporters/co-transporters of glucose such as GLUT1 and other GLUT family members/alternative hexose transporters. In certain embodiments, the compounds have the structure of formula I: wherein the variables have the values disclosed herein.
-
公开(公告)号：US12030857B2
公开(公告)日：2024-07-09
申请号：US16973941
申请日：2019-06-25
发明人： Kevin G. Liu , Kellen L. Olszewski , Ji-In Kim , Masha V. Poyurovsky , Koi Morris , Xuemei Yu , Christophe Lamarque
IPC分类号： C07D239/42 , C07D239/94 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D473/34 , C07D491/048 , C07D491/052 , C07D495/04 , C07D519/00
CPC分类号： C07D239/42 , C07D239/94 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D473/34 , C07D491/048 , C07D491/052 , C07D495/04 , C07D519/00
摘要： This invention provides compounds that modulate glucose uptake activity and cellular transport/uptake of glucose, and particularly GLUTS3, but also including but not limited to GLUT1-14 (SLC2A1-SLC2A14). Compounds of the invention are useful for treating diseases, including cancer, autoimmune diseases and inflammation, infectious diseases, and metabolic diseases.
-
6.发明授权公开(公告)号：US11071735B2
公开(公告)日：2021-07-27
申请号：US16608233
申请日：2018-04-27
发明人： Ji-In Kim , Kellen L. Olszewski , Anthony M. Barsotti , Masha V. Poyurovsky , Kevin G. Liu , Koi Morris , Xuemei Yu
IPC分类号： A61K31/517 , A61P29/00 , A61K31/5377
摘要： This invention provides methods of treating inflammatory conditions and autoimmune diseases in a mammal, comprising administering to the mammalian subject in need thereof a therapeutically effective amount of a compound, or pro-drug thereof, or pharmaceutically acceptable salt or ester of said compound or pro-drug, wherein the compound is an inhibitor of glucose uptake. In particular aspects, the present invention provides a method of treating inflammatory conditions and autoimmune diseases in a mammal, and preferably a human, in which the glucose uptake inhibitor modulates the glucose transport of GLUT1 and GLUT3.
-
公开(公告)号：US10988484B2
公开(公告)日：2021-04-27
申请号：US16397043
申请日：2019-04-29
发明人： Kellen L. Olszewski , Ji-In Kim , Masha V. Poyurovsky , Kevin G. Liu , Anthony Barsotti , Koi Morris
IPC分类号： C07D471/04 , C07D491/04 , C07D495/04 , C07D487/04 , C07D513/04 , A61K45/06 , A61K31/519 , A61K31/52 , A61K31/5377 , C07D473/34 , C07D491/048 , A61P35/04
摘要： Provided herein are compounds that modulate glucose uptake activity and are useful for treating cancer, autoimmune diseases, inflammation, infectious diseases, and metabolic diseases. In certain embodiments, the compounds modulate glucose uptake activity by modulating cellular components, including, but not limited to those related to glycolysis and the known transporters/co-transporters of glucose such as GLUT1 and other GLUT family members/alternative hexose transporters. In certain embodiments, the compounds have the structure of formula I: wherein the variables have the values disclosed herein.
-
8.发明申请公开(公告)号：US20200046702A1
公开(公告)日：2020-02-13
申请号：US16608233
申请日：2018-04-27
发明人： Ji-In Kim , Kellen L. Olszewski , Anthony M. Barsotti , Masha V. Poyurovsky , Kevin G. Liu , Koi Morris , Xuemei Yu
IPC分类号： A61K31/517 , A61K31/5377 , A61P29/00
摘要： This invention provides methods of treating inflammatory conditions and autoimmune diseases in a mammal, comprising administering to the mammalian subject in need thereof a therapeutically effective amount of a compound, or pro-drug thereof, or pharmaceutically acceptable salt or ester of said compound or pro-drug, wherein the compound is an inhibitor of glucose uptake. In particular aspects, the present invention provides a method of treating inflammatory conditions and autoimmune diseases in a mammal, and preferably a human, in which the glucose uptake inhibitor modulates the glucose transport of GLUT1 and GLUT3.
-
公开(公告)号：US10273248B2
公开(公告)日：2019-04-30
申请号：US15737911
申请日：2016-06-24
发明人： Kellen L. Olszewski , Ji-In Kim , Masha V. Poyurovsky , Kevin G. Liu , Anthony Barsotti , Koi Morris
IPC分类号： C07D471/04 , C07D491/048 , C07D487/04 , C07D495/04 , C07D513/04 , A61K45/06 , A61K31/519 , A61K31/52 , A61K31/5377 , C07D473/34 , A61P35/04
摘要： Provided herein are compounds that modulate glucose uptake activity and are useful for treating cancer, autoimmune diseases, inflammation, infectious diseases, and metabolic diseases. In certain embodiments, the compounds modulate glucose uptake activity by modulating cellular components, including, but not limited to those related to glycolysis and known transporters/co-transporters of glucose such as GLUT1 and other GLUT family members/alternative hexose transporters. In certain embodiments, the compounds have the structure of formula I: Formula (I) wherein the variables have the values disclosed herein.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.043 秒)
